| 505 |
0 |
0 |
|g I.
|t Progression and Regression of Atherosclerosis.
|g 1.
|t Regression of Human Aortic Fatty Streaks of Early Life /
|r M. D. Haust --
|g II.
|t Risk Factors for Coronary Heart Disease.
|g 2.
|t Serum Cholesterol as a Risk Factor: Effects of Gender and Age /
|r F. H. Epstein.
|g 3.
|t Influence of Atherogenic Lipoproteins on the Thrombotic Potential of Endothelial Cells /
|r E. Tremoli, M. Camera, S. Colli, L. Sironi, L. Prati, C. Banfi and L. Mussoni.
|g 4.
|t Plurimetabolic Syndrome or Syndrome X. Is it a Real Syndrome? /
|r G. Crepaldi, E. Manzato and R. Nosadini --
|g III.
|t Molecular Biology of Apolipoproteins.
|g 5.
|t Three Liver-Enriched Transcription Factors: HNF-1, C/EBP, and Protein II are Required to Enhance Transcription of the Human Apolipoprotein B Gene /
|r B. Levy-Wilson and A. R. Brooks.
|g 6.
|t Structure-Function Relationships of Apolipoprotein B-100 /
|r L. Chan.
|g 7.
|t Contribution of Helix-Helix Interactions to the Stability of Apolipoprotein-Lipid Complexes /
|r B. Vanloo, M. Rosseneu, M. De Pauw, L. Lins, R. Brasseur and J.-M. Ruysschaert --
|g IV.
|t New Aspects of Lipoprotein Metabolism.
|g 8.
|t Oxidatively Modified LDL and Atherosclerosis /
|r D. Steinberg.
|g 9.
|t Postprandial Hyperlipidemia and Coronary Artery Disease /
|r J. R. Patsch.
|g 10.
|t Genetic Factors Affecting Lipoprotein Metabolism /
|r K. Berg.
|g 11.
|t Lipoprotein Assembly: A Potential Target for Drugs Affecting Lipid Metabolism /
|r R. A. Davis --
|g V.
|t Fatty Acid, Lipase and Triglyceride Metabolism.
|g 12.
|t Structural Features that Determine the Functional Properties of the Loop Region of Human Lipoprotein Lipase /
|r L. C. Smith, R. D. Knapp, F. Faustinella and L. Chan.
|g 13.
|t Molecular Genetics of Lipoprotein Lipase Deficiency /
|r M. R. Hayden and Y. Ma.
|g 14.
|t A New Case of Lipoprotein Lipase Deficiency /
|r A. Capurso, G. Pepe, G. Chimienti, F. Resta, M. Lovecchio and A. M. Colacicco.
|g 15.
|t Modulation of Triglyceride Metabolism by Diet and Drugs /
|r H. J. Pownall, P. Pace, R. D. Knapp, A. M. Gotto, Jr. and P. H. Jones --
|g VI.
|t Reverse Cholesterol Transport - Regulation of Cholesterol Metabolism to Bile Acids.
|g 16.
|t Drugs Affecting Reverse Cholesterol Transport /
|r G. Franceschini, G. Chiesa, L. Calabresi and C. R. Sirtori.
|g 17.
|t High Density Lipoproteins: Function in Reverse Cholesterol Transport and Maintenance of Cellular Integrity /
|r G. Schmitz and K. J. Lackner.
|g 18.
|t The Expression and Regulation of Cholesterol 7[alpha]-Hydroxylase /
|r J. Y. L. Chiang, W. G. Karam, T. P. Yang and D. P. Wang.
|g 19.
|t Cholesterol Metabolism in Normo and Genetically Hyperlipidemic Rats in Aging /
|r G. Galli, M. Cancellieri, S. Baratte, E. De Fabiani and E. Bosisio --
|g VII.
|t LP(A).
|g 20.
|t In Vitro Effect of Thiol- and Cysteine-Containing Compounds on the Immunological Reactivity of Human and Rhesus Monkey Lipoprotein(a) /
|r A. M. Scanu, D. Pfaffinger, G. M. Fless and K. Makino.
|g 21.
|t The Interaction of Lp(a) with Liver Cells: Implications for Lipid Lowering Therapy /
|r G. M. Kostner.
|g 22.
|t Metabolism of Apo(a) and ApoB-100 in Human Lipoprotein(a) /
|r J. D. Morrisett, J. W. Gaubatz, M. N. Nava, J. R. Guyton, A. S. Hoffman, A. R. Opekun and D. L. Hachey --
|g VIII.
|t Antioxidants, Lipoproteins and AtherosclerosisX.
|g 23.
|t Vitamin E-Absorption, Transport in Lipoproteins, Delivery to Tissues and Antioxidant Activity /
|r H. J. Kayden and M. G. Traber.
|g 24.
|t Role of the Macrophage Scavenger Receptor in the 9-Hydroxy-Octadecadienoic Acid Mediated Expression of Interleukin 1[beta] /
|r G. Ku, C. E. Thomas and R. L. Jackson.
|g 25.
|t Oxidative Damage to Circulating LDL /
|r P. Avogaro, G. Cazzolato, D. M. Kramsch, A. Sevanian, H. Hodis and G. Bittolo Bon --
|g IX.
|t Drugs Affecting Atherosclerosis and Thrombosis.
|g 26.
|t Dietary Advice for the Prevention of Arterial Thrombosis /
|r M. Mancini, A. Rivellese and G. Di Minno.
|g 27.
|t Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism /
|r A. M. Gotto, Jr.
|g 28.
|t Drugs Affecting Thrombosis and Atherosclerosis /
|r C. R. Sirtori and S. Colli.
|g 29.
|t Lipid Lowering: Progression and Regression of Atherosclerotic Lesions /
|r D. H. Blankenhorn /
|r MARS and CLAS Study Groups.
|g 30.
|t Clinical Trials of Atherosclerosis Regression /
|r B. Lewis.
|g 31.
|t Biochemical Mechanisms Associated with the Lipolytic Effects of Calcium Channel Blockers /
|r K. B. Pomerantz, A. C. Nicholson, O. Etingin, B. Summers and D. P. Hajjar --
|g X.
|t New Aspects of Hypolipidemic Therapy.
|g 32.
|t Pravastatin Reduces Plasma Concentration of a More Electronegatively Charged LDL Subfraction in FH /
|r G. Bittolo-Bon, G. Cazzolato, P. Alessandrini and P. Avogaro.
|g 33.
|t Clinical Experience with Flavastatin, the First Synthetic HMG-CoA Reductase Inhibitor /
|r L. A. Jokubaitis, A. J. Troendle, J. M. Fattu and R. I. Levy.
|g 34.
|t Secondary Prevention of Cardiovascular Disease: The Role of HMG-CoA Reductase Inhibitors /
|r J. C. LaRosa.
|g 35.
|t Combined Drug Treatment of Severe Hypercholesterolemia /
|r P. Schwandt.
|g 36.
|t Regression of Coronary Atherosclerosis by LDL-Apheresis /
|r A. Yamamoto, Y. Goto, Y. Nakashima, T. Yasugi, Y. Okamura, Y. Saito, T. Nishide, N. Inoue, N. Koga, B. Kishino, H. Ito, T. Teramoto and R. Tatami.
|g 37.
|t Partial Ileal Bypass - Results of the Program on the Surgical Control of the Hyperlipidemias (POSCH) /
|r C. T. Campos and H. Buchwald /
|r POSCH Group.
|g 38.
|t Hypercholesterolemia: Negotiating the Issues /
|r J. C. LaRosa.
|g 39.
|t Antiatherosclerotic Drugs: A Critical Assessment /
|r M. Raiteri, A. Corsini, M. R. Soma, E. Donetti, F. Bernini, R. Fumagalli and R. Paoletti --
|g A.
|t HDL and Atherosclerosis.
|g 40.
|t Experimental and Clinical Evidence for a Protective Role of High-Density Lipoprotein in Coronary Heart Disease /
|r A. M. Gotto, Jr., W. Patsch and J. R. Patsch.
|g 41.
|t HDL as a Risk Factor for Coronary Heart Disease: An Update on the Helsinki Heart Study /
|r V. Manninen and M. Manttari.
|g 42.
|t Relationship of HDL Cholesterol to Incidence of Atherosclerotic Coronary Heart Disease: The PROCAM Experience /
|r G. Assmann, A. von Eckardstein and H. Schulte.
|g 43.
|t The Clinical Approach to the Patients with Low HDL and Elevated Plasma Triglyceride /
|r A. Notarbartolo, M. R. Averna and C. M. Barbagallo --
|g B.
|t Atherosclerosis: A Multifactorial Approach.
|g 44.
|t Familial Lipoprotein Disorders in Patients with Premature Coronary Artery Disease /
|r E. J. Schaefer, J. M. Ordovas, P. W. F. Wilson, D. N. Salem and J. J. Genest, Jr.
|g 45.
|t Efficacy of Fenofibrate on Plasma Cholesterol in Swine with Spontaneous Hypercholesterolemia /
|r J. Rapacz, J. Hasler-Rapacz and A. D. Edgar.
|g 46.
|t Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication /
|r J. C. Fruchart.
|g 47.
|t Fibrinogen: Pathogenetical and Therapeutical Implications in Atherosclerosis /
|r M. Leschke, M. M. Borst, O. Rabenau, F. C. Schoebel and B. E. Strauer.
|g 48.
|t Regression and Decrease in Progression of Coronary Artery Disease Through Lipid-Lowering Therapy /
|r H. W. Hahmann --
|g C.
|t Antioxidants and Lipid Metabolism: New Directions in the Management of Atherosclerosis and Hyperlipidemia.
|g 49.
|t Glycation and Oxidation of Proteins: A Role in the Pathogenesis of Atherosclerosis? /
|r T. J. Lyons.
|g 50.
|t A Modern View of Atherogenesis /
|r C. J. Schwartz.
|g 51.
|t Defective Catabolism of Oxidized LDL by J774 Murine Macrophages /
|r P. Roma, F. Bernini, R. Fogliatto, S. M. Bertulli, S. Negri, R. Fumagalli and A. L. Catapano.
|g 52.
|t Analysis of Lipid vs. Non-Lipid Effect on Atherosclerosis Development /
|r J. Regnstrom, J. Nilsson, A. G. Olsson, L. A. Carlson, U. Erikson and G. Walldius --
|g D.
|t Triglyceride Rich Lipoproteins: Atherogenesis and Hemostasis.
|g 53.
|t Atherogenicity of Triglyceride-Rich Lipoproteins: Cellular Aspects /
|r S. H. Gianturco, F. M. Booyse and W. A. Bradley.
|g 54.
|t Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects /
|r J. Shepherd, M. Caslake, A. Gaw, B. Griffin, G. Lindsay and C. Packard.
|g 55.
|t Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia /
|r M. R. Taskinen.
|g 56.
|t Effects of Fibrates on the Altered Lipoprotein System in Hypertriglyceridemia /
|r S. Eisenberg.
|g 57.
|t Triglyceride-Rich Lipoprotein: Role in Atherogenesis and Haemostasis /
|r C. R. Sirtori and M. R. Lovati --
|g E.
|t HDL, Phospholipids and Atherosclerosis.
|
